Skip to content

Presentations

LATEST COMPANY PRESENTATIONS AND INTERVIEWS

PILA PHARMA x REDEYE H1 Report & Q&A [August 29, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram participates in a online Investor Forum with Redeye and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with Analyst Filip Einarsson, answering investor questions about PILA PHARMA, the market and global trends for Diabetes, Obesity and Cardiovasculardisease that PILA aims to tap into.

The presentation & Q&A is conducted (in English) here

PILA PHARMA x AKTIESPARARNA – H1 Report & Q&A [August 28, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram participates in a online Life Science evening with Aktiespararna and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with Analyst Filip Lindkvist, answering investor questions about PILA PHARMA, the market and global trends for Diabetes, Obesity and Cardiovascular disease that PILA aims to tap into.

The presentation & Q&A is conducted (in English) here

PILA PHARMA x Stokk.io – H1 Report & Q&A [August 27, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram hosts a webinar with Stokk.io and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with investor questions about PILA PHARMA. In this questions about the market and global trends for Diabetes, obesity and cardiovascular disease that PILA aims to tap into are answer.

The presentation & Q&A is conducted (in English) here

Founder, Inventor, CSO and Chairman of PILA PHARMA, Dr. Dorte X. Gram presents the short PILA PHARMA story and rationale behind treatment of metabolic conditions with a TRPV1 / Capsaicin receptor antagonist, to the DNSG 2024 Symposium, the 41st International Symposium on Diabetes and Nutrition, which took place in Uppsala, Sweden on June 27th – 30th, 2024.

Please, find the link to the video (in English) here

Aktiespararna June 12th, 2024

PILA PHARMA’s CEO, Mr. Gustav H. Gram presents the company.

Please, find the link to the video (in English) here

PILA PHARMA’s CEO, Mr. Gustav H. Gram provides an insight into the market and global trends for Diabetes, obesity and cardiovascular disease that PILA aims to tap into. The presentation and Q&A is conducted in English.

Please, find the link to the video (in English) here

(31 May-2024)

Newly appointed CEO, Gustav H. Gram, hosts a Q&A with Stokk.io on PILA PHARMA’s changes with Founder Dorte X. Gram transitioning to Chairman of the Board and what changes and direction that investors can expect. The Q&A is conducted in English together with Anders Egsvang from Stokk.io on April 22nd, 2024.

Please, find the link to the video (in English) here

Aktiespararna Online Lifescience Day (ONLINE / Stockholm, Sweden)

Please, find the link to the video (in English) here

(17 April-2024)

Dansk Aktionærforening Fyn [INVESTOR DAGEN] (Odense, Denmark)

Please, find the link to the video (in English) here

(16 April-2024)

Redeye Online Investor Event (ONLINE / Stockholm, Sweden)

Please, find the link to the video (in English) here

(11 April-2024)

AktieInfo Investor Evening (Scandic Sydhavnen, Copenhagen, Denmark)

Please, find the link to the video (in Danish) here

(21 March-2024)

Q&A on PILA PHARMA’s Q4 report and the outlook for 2024 with PILA PHARMA’S innovative take on an alternative route to treating obesity, diabetes and cardiovascular disease together with Anders Egsvang from Stokk.io

Please, find the link to the video (in English) here

(28 February-2024)

PIla Pharma CEO Dorte X. Gram discusses with financial markets expert Richard Busellato on the obesity market, considerations of investing in pharma and how future solutions could look like including Pila Pharma’s novel tablet based #TRPV1-antagonist treatment

Please, find the link to the video (in English) here

(01 December-2023)

Our CEO Dorte X. Gram presented the Company and ongoing Rights Issue at Aktiespararna event Stora Aktiedagen i Stockholm

Please, find the link to the video (in English) here

(27 November-2023)

Our CEO Dorte X. Gram presented the Company and ongoing Rights Issue to the Danish young-investor group “Unge Investorer”

Please, find the link to the video (in Denish) here

(27 November-2023)

Our CEO Dorte X. Gram presents at Redeye Life Science Day 2023

Please, find the link to the video (in English) here

(23 November-2023)

Proinvestor – Pila Pharma vil lave en tablet mod fedme og diabetes
En mere teknisk introduktion til PILA PHARMA

For more information, please visit the following link here

(16 November-2023)

Today we paid a visit to the impressive clinical site in Cambridge where we plan to carry out our next phase 2 trial with XEN-D0501 in obese people with diabetes.
Happy worlddiabetesday to all!

Please, find the link to the video (in English) here

(14 November-2023)

CEO & Founder Dorte X. Gram presents PILA PHARMA’s innovative take on an alternative route to treating obesity, diabetes and cardiovascular disease at the LSX Inv€$tival conference in London.

Please, find the link to the video (in English) here

(13 November-2023)

Dansk Aktionærforening: Kom med på rejsen mod mere effektiv fedmebehandling
En god introduktion til PILA PHARMA

For more information, please visit the following link here

(07 November-2023)

Presentation by PILA PHARMA CEO, Dr. Dorte X. Gram at the LSXNordic Congress on 11/10/2023 on the case of TRPV1 antagonist XEN-D0501 as a novel treatment of obesity and type-2 diabetes.

In the presentation, Dr. Gram presents some previously undisclosed data on a heartfailure marker (ANP) further strengthening the case for XEN-D0501 as a safe and potent molecule for its class with benificial cardiometabolic effects.

Please, find the link to the video (in English) here
(19 Oct-2023)
Pila Pharma ProHearings
Our CEO Dorte X Gram visited ProHearings on 23-09-29 and gave an investor presentation.
Please, find the link to the video (in English) here
(03 Oct-2023)
QU Life Science
Yesterday, our CEO Dorte Xenia Gram had the pleasure of presenting a deep-dive in the history of PILA PHARMA PILA to Danish investors, where we fit in with the new obesity & diabetes treatments and some previously undisclosed positive data on a heartfailure marker! 😉
Please, find the link to the video (in Danish) here
(29 Sep-2023)
Financial Stockholm

On August 28, 2023 in Finans Stockholm, our CEO For Dorte X Gram gave some hints at how PILA PHARMA will proceed and be relevant with our TRPV1 antagonist treatment.

Please, find the link to the video (in English) here

(07 Sep-2023)

Live from San Diego! Takeaways from this years ADA2023, the American Diabetes association yearly congress.
Hear our CEO, Dorte X. Gram’s thoughts on the trends and developments in the diabetes and obesity space.
Please, find the link to the video (in English) here

(27 June-2023)

CEO of Pila Pharma, Dorte X. Gram, interviews Matt Sondag about the thoughts and challenges of a living with erythromelalgia, a rare disease with periods of intense pain.
Please, find the link to the video (in English) here

(2 June-2023)
Back To Top